Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Intra-nasal vaccination
- 30 January 2008
- Vol. 26 (5) , 664-676
- https://doi.org/10.1016/j.vaccine.2007.11.045
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- Suppression of Proinflammatory Signal Transduction and Gene Expression by the DualNucleic Acid Binding Domains of the Vaccinia Virus E3L ProteinsJournal of Virology, 2006
- Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccineVaccine, 2005
- Myopericarditis following Smallpox VaccinationAmerican Journal of Epidemiology, 2004
- Incidence and follow-up of inflammatory cardiac complications after smallpox vaccination11The views expressed in this study are those of the authors and do not reflect the official policy or position of the U.S. government.Journal of the American College of Cardiology, 2004
- Mouse neurotoxicity test for vaccinia-based smallpox vaccinesVaccine, 2004
- Control of a Mucosal Challenge and Prevention of AIDS by a Multiprotein DNA/MVA VaccineScience, 2001
- Both Carboxy- and Amino-Terminal Domains of the Vaccinia Virus Interferon Resistance Gene, E3L, Are Required for Pathogenesis in a Mouse ModelJournal of Virology, 2001
- In VivoDelivery of Interleukin-4 by a Recombinant Vaccinia Virus Prevents Tumor Development in MiceHuman Gene Therapy, 1994
- Identification of a Conserved Motif That Is Necessary for Binding of the Vaccinia Virus E3L Gene Products to Double-Stranded RNAVirology, 1993
- Vaccinia virus: a suitable vehicle for recombinant vaccines?Archiv für die gesamte Virusforschung, 1989